Cerecor Inc (NASDAQ:CERC), a pharmaceuticals company based in United States, led the NasdaqCM gainers with a relatively large price hike in the past couple of weeks. As a small cap stock, hardly covered by any analysts, there is generally more of an opportunity for mispricing as there is less activity to push the stock closer to fair value. Is there still an opportunity here to buy? Today I will analyse the most recent data on Cerecor’s outlook and valuation to see if the opportunity still exists. Check out our latest analysis for Cerecor
Is Cerecor still cheap?
Great news for investors – Cerecor is still trading at a fairly cheap price. According to my valuation, the intrinsic value for the stock is $12.14, which is above what the market is valuing the company at the moment. This indicates a potential opportunity to buy low. However, given that Cerecor’s share is fairly volatile (i.e. its price movements are magnified relative to the rest of the market) this could mean the price can sink lower, giving us another chance to buy in the future. This is based on its high beta, which is a good indicator for share price volatility.What kind of growth will Cerecor generate?
What this means for you:
Are you a shareholder? Although CERC is currently undervalued, the adverse prospect of negative growth brings about some degree of risk. Consider whether you want to increase your portfolio exposure to CERC, or whether diversifying into another stock may be a better move for your total risk and return.
Are you a potential investor? If you’ve been keeping tabs on CERC for some time, but hesitant on making the leap, I recommend you dig deeper into the stock. Given its current undervaluation, now is a great time to make a decision. But keep in mind the risks that come with negative growth prospects in the future.
Price is just the tip of the iceberg. Dig deeper into what truly matters – the fundamentals – before you make a decision on Cerecor. You can find everything you need to know about Cerecor in the latest infographic research report. If you are no longer interested in Cerecor, you can use our free platform to see my list of over 50 other stocks with a high growth potential.
Valuation is complex, but we're here to simplify it.
Discover if Avalo Therapeutics might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
Simply Wall St analyst Simply Wall St and Simply Wall St have no position in any of the companies mentioned. This article is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.